MCC Therapeutics, Inc. received funding from Capital-K, a venture fund, Portola Valley, CA. MCC Therapeutics licensed the technology, discovered by its founders, from Stanford University.

We initiated operations to advance our drug MCCSA2 into clinical development. The company is engaged in inhalation formulation development. These studies will enable us to manufacture the drug for clinical studies.

We plan to initiate a Phase 1 study of single ascending dose of MCCSA2 followed by a 28-day multiple dose study in patients with bronchiectasis. We plan to capture safety and efficacy outcomes including spirometry, CT scanning and patient reported quality of life measures. We believe following demonstration of safety and early signal of efficacy MCCSA2 can advance rapidly throughout clinical trials.

Inhibited or dysfunctional mucociliary clearance is experienced across many lung diseases. MCC Therapeutics plans to initiate studies improving dysfunctional mucociliary clearance in bronchiectasis. We later plan to study the drug in patients with cystic fibrosis, COPD and asthma.

We are currently engaged in fundraising of a Series A supporting the clinical development of MCCSA2.

MCCSA2

MCCSA2 is composed of inhaled Formoterol Fumarate and Methacholine Chloride. Alone, formoterol is commonly used in airway diseases as a bronchodilator. Alone, methacholine results in bronchoconstriction which is not seen with the proposed combination. The founders of MCC Therapeutics, while at Stanford University, discovered that the simultaneous administration of the two drugs results in synergistic regulation of inhibited mucociliary clearance. The combination, MCCSA2, results in increased ASL secretion and decreased absorption, improved ciliary beat velocity without airway narrowing. The effect is independent of CFTR function and observed across multiple animal species.

In a single ascending dose study in healthy volunteers, followed by patients with cystic fibrosis, taking Trikafta, we observed no adverse effects. More so, we observed an early signal of improvement in mucus clearance demonstrated by spirometry and induced sputum analysis.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of MCC Therapeutics, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. MCC Therapeutics, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.